Last 27.00 INR
Change Today 0.00 / 0.00%
Volume 0.0
As of 6:00 AM 08/19/14 All times are local (Market data is delayed by at least 15 minutes).

krebs biochemicals & industr (KBC) Snapshot

Open
29.95
Previous Close
27.00
Day High
30.00
Day Low
27.00
52 Week High
08/12/14 - 34.00
52 Week Low
12/4/13 - 9.42
Market Cap
256.9M
Average Volume 10 Days
1.4K
EPS TTM
-24.58
Shares Outstanding
9.5M
EX-Date
09/14/05
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KREBS BIOCHEMICALS & INDUSTR (KBC)

Related News

No related news articles were found.

krebs biochemicals & industr (KBC) Related Businessweek News

No Related Businessweek News Found

krebs biochemicals & industr (KBC) Details

Krebs Biochemicals & Industries Limited, a biochemical company, engages in the manufacture and sale of active pharmaceutical ingredients and intermediates in India. It develops biotech processes for application in medicine, agriculture, and industry. The company provides various products for application as anti cholesterols and anti asthmatics. It is also developing an intermediate for Tenofovir Anti HIV; and various products for anti cholesterol, cough and cold, and anti obesity therapeutic areas. The company was founded in 1991 and is based in Hyderabad, India.

Founded in 1991

krebs biochemicals & industr (KBC) Top Compensated Officers

Chairman of The Board, Managing Director, Mem...
Total Annual Compensation: 1.2M
Chief Operating Officer, Compliance Officer a...
Total Annual Compensation: 1.1M
Compensation as of Fiscal Year 2012.

krebs biochemicals & industr (KBC) Key Developments

Krebs Biochemicals & Industries Ltd. Appoints R. Ch. Satyanarayana as Independent Director

Krebs Biochemicals & Industries Ltd. announced that the Board of Directors of the Company at its meeting held on August 13, 2014, appointed Mr. R. Ch. Satyanarayana as Independent Director on the Board.

Krebs Biochemicals & Industries Ltd Reports Unaudited Standalone Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2014

Krebs Biochemicals & Industries Ltd. reported unaudited standalone earnings results for the fourth quarter and full year ended June 30, 2014. For the quarter, the company reported loss from operations before other income, finance costs and exceptional items of INR 6.707 million against INR 10.947 million a year ago. Profit from ordinary activities before tax was INR 25.130 million against INR 74.662 million a year ago. Net profit for the period was INR 25.130 million against INR 74.662 million a year ago. Basic and diluted earnings per share were INR 2.64 against INR 7.85 a year ago. For the year, the company reported loss from operations before other income, finance costs and exceptional items of INR 67.857 million against INR 129.375 million a year ago. Loss from ordinary activities before tax was INR 36.750 million against INR 111.431 million a year ago. Net profit for the period was INR 36.750 million against INR 111.431 million a year ago. Basic and diluted earnings per share were INR 3.86 against INR 11.71 a year ago.

Krebs Biochemicals & Industries Ltd, Board Meeting, Aug 13, 2014

Krebs Biochemicals & Industries Ltd, Board Meeting, Aug 13, 2014. Agenda: To consider unaudited standalone earnings results for the fourth quarter and full year ended June 30, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KBC:IN 27.00 INR 0.00

KBC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KBC.
View Industry Companies
 

Industry Analysis

KBC

Industry Average

Valuation KBC Industry Range
Price/Earnings 50.8x
Price/Sales 73,684.1x
Price/Book 25.7x
Price/Cash Flow 45.2x
TEV/Sales 53,684.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KREBS BIOCHEMICALS & INDUSTR, please visit www.krebsbiochem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.